If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Trulicity ® (dulaglutide) injection
0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3mg/0.5mL, 4.5mg/0.5mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can Trulicity® (dulaglutide) be used with DPP-4 Inhibitors?
The use of sitagliptin in combination with Trulicity (dulaglutide) was not evaluated in clinical studies.
Coadministration of Dulaglutide With Sitagliptin
An open-label, 2-period, crossover, clinical pharmacology study was done in 29 patients with T2DM that evaluated the mutual effects on the PK of both dulaglutide 1.5 mg and sitagliptin 100 mg.1
Potential for Dulaglutide to Influence the Pharmacokinetics of Sitagliptin
Dulaglutide is a human GLP-1 RA that causes a delay in gastric emptying.2
The delay is longest after the first dose of dulaglutide diminishes with subsequent doses.2
Because dulaglutide slows gastric emptying, it may reduce the extent and rate of absorption of orally coadministered medications.2
Caution should be exercised when oral medications are taken concomitantly with dulaglutide.2
Based on the analysis,
no clinically significant effect on the PK of sitagliptin was seen, and
Figure 1. Impact of Dulaglutide on the Pharmacokinetics of Coadministered Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin2
Potential for Coadministered Sitagliptin to Influence the Pharmacokinetics of Dulaglutide
Compared to dulaglutide being taken alone, the coadministration of a single dose of dulaglutide 1.5 mg with steady-state sitagliptin 100 mg resulted in dulaglutide's increase in
the area under the AUC by approximately 38%
Cmax by approximately 27%, and
The authors did not consider these differences in the PK profile clinically relevant.1
Enclosed Prescribing Information
1. Geiser J, de la Peña A, Cui X, et al. No dose adjustment is needed when coadministering dulaglutide with once-daily sitagliptin. Poster presented at: American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting: March 15-18, 2017; Washington, D.C.
AUC = area under the curve
Cmax = maximum plasma concentration
DPP-4 = dipeptidyl peptidase-4
GLP-1 RA = glucagon-like peptide-1 receptor agonist
PK = pharmacokinetic
T2DM = type 2 diabetes mellitus
Tmax = time to maximum concentration
Date of Last Review: June 24, 2020